DK1250152T3 - Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer - Google Patents

Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer

Info

Publication number
DK1250152T3
DK1250152T3 DK00986939.7T DK00986939T DK1250152T3 DK 1250152 T3 DK1250152 T3 DK 1250152T3 DK 00986939 T DK00986939 T DK 00986939T DK 1250152 T3 DK1250152 T3 DK 1250152T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
composition containing
hyaluronic acid
synergistic composition
Prior art date
Application number
DK00986939.7T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Urology Ip Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Urology Ip Inc filed Critical Bioniche Urology Ip Inc
Application granted granted Critical
Publication of DK1250152T3 publication Critical patent/DK1250152T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK00986939.7T 1999-12-28 2000-12-28 Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer DK1250152T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17337599P 1999-12-28 1999-12-28
PCT/CA2000/001562 WO2001047561A1 (en) 1999-12-28 2000-12-28 Hyaluronic acid in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1250152T3 true DK1250152T3 (da) 2013-08-26

Family

ID=22631719

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00986939.7T DK1250152T3 (da) 1999-12-28 2000-12-28 Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer

Country Status (8)

Country Link
US (1) US7125858B2 (da)
EP (1) EP1250152B1 (da)
JP (1) JP4215429B2 (da)
AU (1) AU784356B2 (da)
CA (1) CA2395493C (da)
DK (1) DK1250152T3 (da)
NZ (1) NZ520312A (da)
WO (1) WO2001047561A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374163C (zh) 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 增强药物功效的组合物
CN101491536B (zh) * 1999-12-13 2012-07-04 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
WO2002061085A2 (en) 2000-10-31 2002-08-08 Ryan James W Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
JP4851185B2 (ja) 2003-05-16 2012-01-11 ジェレックスインターナショナル株式会社 アレルギー症状抑制剤及び空気濾過フィルター
US20060240084A1 (en) * 2005-04-20 2006-10-26 Xylos Corporation Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use
EP1912658B1 (en) * 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
JP5627181B2 (ja) 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
DE102009035586A1 (de) 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs
CN102791861B (zh) 2009-09-25 2018-08-07 库尔纳公司 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病
DK2571979T3 (da) 2010-10-13 2020-09-28 Telesta Therapeutics Ip Inc Bakterielle ribonukleinsyre-cellevæg-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2015036576A1 (en) * 2013-09-12 2015-03-19 Dsm Ip Assets B.V. Ocular device
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
JP2021031453A (ja) * 2019-08-27 2021-03-01 国立研究開発法人物質・材料研究機構 炎症性サイトカイン産生抑制材、ヒアルロン酸誘導体、及び、ヒアルロン酸誘導体の製造方法。
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (da) * 1971-11-19 1975-02-07 Anvar
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3408768A1 (de) 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0247071B1 (en) 1985-10-31 1993-09-22 The Australian National University Immunotherapeutic treatment
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4837202A (en) 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
DE3818054C2 (de) 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1998017320A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
CA2122519C (en) 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
WO1994016727A1 (en) 1993-01-29 1994-08-04 Vetrepharm, Inc. Immunotherapeutic composition
AU6362594A (en) 1993-03-10 1994-09-26 Miles Inc. Hyaluronic acid used as a cancer treatment
IN181358B (da) * 1995-02-14 1998-05-30 Bioniche Inc
AU1991097A (en) 1996-03-15 1997-10-01 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6326357B1 (en) * 1997-08-05 2001-12-04 Bioniche Life Sciences Inc. Bacterial cell complex composition and method of use
PT1054680E (pt) 1998-02-18 2005-06-30 Bioniche Life Sciences Inc Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei
DE69920506T2 (de) 1998-12-04 2005-10-13 Bioniche Life Sciences Inc., London Chemotherapeutische zusammensetzung und verfahren
CN100374163C (zh) * 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 增强药物功效的组合物
CA2266188A1 (en) 1999-03-19 2000-09-19 Stephen Chizick Natural preparation for treatment of male pattern hair loss

Also Published As

Publication number Publication date
US20030176381A1 (en) 2003-09-18
WO2001047561A1 (en) 2001-07-05
JP4215429B2 (ja) 2009-01-28
EP1250152B1 (en) 2013-05-15
EP1250152A1 (en) 2002-10-23
CA2395493C (en) 2010-06-22
NZ520312A (en) 2003-08-29
US7125858B2 (en) 2006-10-24
CA2395493A1 (en) 2001-07-05
JP2003518510A (ja) 2003-06-10
AU784356B2 (en) 2006-03-16
AU2336401A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
DK2412368T3 (da) Sammensætning til behandling af ar
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
DK1250152T3 (da) Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
DK1173059T3 (da) Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
DK1384478T3 (da) Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
DK1450606T3 (da) Synergistiske sammensætninger til behandling af såsæd
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DK1156806T3 (da) Farmaceutisk sammensætning indeholdende protonpumpeinhibitor
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
DK1150681T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
IL133760A0 (en) Composition for the treatment of dandruff
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
NO20022000D0 (no) 6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
DE10080787D2 (de) Mikrobiozide Zusammensetzung
HK1043938A1 (en) Composition for the treatment of psoriasis
ATE286391T1 (de) Synergistische zusammensetzung zur krebsbehandlung